Writing in the Los Angeles Times, UC San Diego pediatrician Joshua Rothman argues that federal vaccine policy changes are setting up a resurgence of hepatitis B in infants after his study found newborn hepatitis B vaccination rates fell by more than 10% between 2023 and August 2025. He says hepatitis B once infected about 18,000…

Chief nursing officers say telehealth nurses and virtual nurses are their top hiring priorities for 2026, according to a Wolters Kluwer survey of 150 hospital and health system leaders reported by Becker’s. Telehealth nurses ranked first and virtual nurses second, reflecting growing demand for remote care delivery models that can support staffing flexibility and care…

Signature Healthcare and Signature Healthcare Brockton Hospital activated incident response protocols after detecting suspicious network activity that disrupted parts of their information systems. The outage forced the system onto downtime procedures and alternative documentation workflows, while inpatient care, emergency walk-in services, surgeries, endoscopy, ambulatory practices, and urgent care remained open with expected delays. Ambulances were…

President Trump’s 2027 budget proposal would cut Department of Health and Human Services funding by more than 12%, reducing the agency’s budget to about $111.1bn and trimming roughly $15.8bn overall. The plan includes a $5bn reduction for the National Institutes of Health, elimination of some research centers, and shutdown of programs serving refugees and low-income…

Supporters of HHS Secretary Robert F. Kennedy Jr. are urging President Trump to appeal a court ruling threatening the administration’s vaccine policy overhaul. The dispute centers on federal vaccine rules affecting childhood immunization policy nationwide, with implications for pediatric providers and public health agencies. Kennedy’s allies view the case as central to the administration’s “Make…

Oric Pharmaceuticals has selected a 400-mg dose for its prostate cancer drug rinzimetostat, moving into phase 3 trials. The trial will test the drug with Bayer’s Nubeqa in patients with metastatic castration-resistant prostate cancer. Interim results showed a 33% decline in PSA levels, but Oric’s stock fell 24% due to investor concerns over the dose…